HA
VIVO

Havens Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

Havens Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$890K Sell
26,800
-50,200
-65% -$1.62M 2.26% 17
2022
Q3 		$2.43M Buy
+77,000
New +$2.49M 3.63% 16

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Havens Advisors's VIVO Position: Q4 2022 in Review

Havens Advisors reduced its Meridian Bioscience Inc (VIVO) stake by 65% in Q4 2022, selling an estimated $1.62M and leaving 26,800 shares worth $890K. The position accounts for 2.26% of the portfolio, ranked #17.

Havens Advisors first reported a position in VIVO in Q3 2022 and has held it in 2 quarters since. The position peaked at $2.43M in Q3 2022. 218 funds tracked by Wall St. Rank hold VIVO as of Q4 2022.

  • Havens Advisors held 26,800 shares of Meridian Bioscience Inc worth $890K as of Q4 2022.
  • Havens Advisors sold 50,200 Meridian Bioscience Inc shares in Q4 2022, an estimated $1.62M.
  • Meridian Bioscience Inc made up 2.26% of Havens Advisors's portfolio in Q4 2022, its #17 holding.
  • Havens Advisors first reported a position in Meridian Bioscience Inc in Q3 2022 and has held it in 2 quarters since.
  • Havens Advisors's Meridian Bioscience Inc position peaked at $2.43M in Q3 2022.
  • 218 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2022.

Based on Havens Advisors's 13F filing for Q4 2022, filed 25 Jan 2023.